Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,

Slides:

Advertisements

Similar presentations

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

Advertisements

NKF-KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease UPDATE OF HEMOGLOBIN TARGET Am.J.Kidney.Dis.

Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.

RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

1 Pre-Specified Outcomes All primary and secondary outcomes and their components were pre-specified, i.e., they appeared in the protocol, manual of operations.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.

Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

신장내과 R4 강혜란 Cardiorenal syndrome (CRS).  Patients with heart failure (HF) who have a reduced GFR -> Mortality ↑  Patients with chronic kidney disease.

R1. 이용석 / modulator pf. 임천규. Introduction Autosomal dominant polycystic kidney disease (ADPKD) is characterized by gradual cyst enlargement over a period.

Nephrology Journal Club The SPRINT Trial Parker Gregg

The LIVES Sub-analysis

Assessment of Achieved Clinic and Ambulatory Blood Pressure Recordings and Outcomes During Treatment in Hypertensive Patients With CKD: A Multicenter.

NYHA III* or IV heart failure ACE-I + loop diuretic ± digoxn

Prior Trials of RAAS Inhibitors

Diabetic Dyslipidemia in Practice

CLINICAL DILEMMAS IN HEART FAILURE:

Emerging Concepts in Heart Failure

Current State of Hyperkalemia Management

Assessment of Achieved Clinic and Ambulatory Blood Pressure Recordings and Outcomes During Treatment in Hypertensive Patients With CKD: A Multicenter.

Advancing Management of Anemia With the Latest Data From ERA-EDTA 2018

New and Emerging Management Options for Anemia in CKD

An Endocrinology Clinic in Dyslipidemia

PCP Perspectives Pathophysiologic Principles in the Management of Hyperkalemia.

Hyperkalemia in the Hospital: Collaboration to Improve Transitions of Care.

New Therapies for Hyperkalemia Across the Continuum of Care

A CASE CHALLENGE IN HFrEF:

At The Cutting Edge of Developments in the Management of Hyperkalemia

Updates Abound in Hyperkalemia Management

Select Topics in Cardiovascular Medicine

PCP Perspectives Clinical Considerations in Hyperkalemia

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Expert Perspectives on Hyperkalemia for the Specialist

Exploring Emerging Treatments for Hyperkalemia

Tackling CV Risk in T2DM.

At The Cutting Edge of Developments in the Management of Hyperkalemia

Deborah J. Clegg, PhD, Michael Cody, MD, Biff F. Palmer, MD

Multidisciplinary Management of Hyperkalemia:

Shifting Currents in Hyperkalemia Management 2015 in Review

Shifting Currents in Hyperkalemia Management 2015 in Review

End point Fenoldopam, n (%) Dopamine, n (%) p

ALBATROSS Trial design: Patients with MI without heart failure were randomized to an IV bolus of potassium canrenoate 200 mg as early as possible, then.

Challenging the Myths in Heart Failure With Reduced Ejection Fraction

CAD and HF Often Coexist

I. Introduction American Journal of Kidney Diseases

Nat. Rev. Cardiol. doi: /nrcardio

Meeting the challenges of the new K/DOQI guidelines

Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.

Assessing the Burden of Hyperkalemia

Breaking Down the Data in Hyperkalemia

Assessing the Burden of Hyperkalemia

Lynda Anne Szczech, Ira L. Lazar Kidney International

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

What's New in Oral Combination Therapy for Type 2 Diabetes?

Emerging Advances in Reducing Renal Complications of T2D

Lipids, the Heart, and the Kidney

Clinical Comparisons.

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

Top Tips in Evidence-Based Care for HFrEF

RAASi Enabling in the Modern Era

Case-Based Look at Hyperkalemia Identification, Diagnosis, and Management.

Potassium Situations Resolved

Presentation transcript:

Introduction: Alarming Statistics

Causes of Death in Prevalent Dialysis Patients, 2009-2011

Risk Factors for CVD in Patients With CKD and ESRD

Management of Patients With ESRD and CVD

Use of RAAS Inhibitors in CKD and ESRD

RAAS Inhibitor Use in Patients With Advanced Kidney Disease

Safety and Efficacy of MRAs in Patients on Dialysis

Benefits of MRAs

Aldosterone Antagonists in HF Clinical Trial Results

Use of MRAs in Patients With Renal Impairment

Dialysis Outcomes Heart Failure Aldactone Study

Long-Term Effects of Spironolactone in Patients on Dialysis

Upcoming Trials Use of MRAs in Patients With ESRD

Managing Potassium Levels in Patients With HF and Reduced Renal Function

Potassium and Creatinine Testing in Patients With HF Starting MRA Therapy

Treatment Options for Hyperkalemia

SPS for the Treatment of Hyperkalemia

Patiromer Adverse Events*